Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 9/20 | 0.57 |
| ▸ | KDR | P35968 | 8/20 | 0.57 |
| ▸ | PRKCQ | Q04759 | 7/20 | 0.57 |
| ▸ | PRKCA | P17252 | 6/20 | 0.57 |
| ▸ | FLT3 | P36888 | 4/20 | 0.57 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.57 |
| ▸ | PRKCH | P24723 | 4/20 | 0.57 |
| ▸ | PRKCI | P41743 | 4/20 | 0.57 |
| ▸ | PRKCE | Q02156 | 4/20 | 0.57 |
| ▸ | PRKCD | Q05655 | 4/20 | 0.57 |
| ▸ | PRKD1 | Q15139 | 4/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.57 |
| ▸ | CDK4 | P11802 | 3/20 | 0.57 |
| ▸ | CDK2 | P24941 | 3/20 | 0.57 |
| ▸ | MYLK | Q15746 | 3/20 | 0.57 |
| ▸ | MAP3K11 | Q16584 | 3/20 | 0.57 |
| ▸ | CAMKK2 | Q96RR4 | 3/20 | 0.57 |
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.57 |
| ▸ | JAK2 | O60674 | 2/20 | 0.57 |
| ▸ | EIF2AK2 | P19525 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24991353 | 0.74 | EIF2AK2 (0.63) | NTRK1KDRPRKCQPRKCAFLT3 | |
| SCHEMBL30464954 | 0.73 | EIF2AK2 (0.66) | NTRK1KDRPRKCQPRKCAFLT3 | |
| Lestaurtinib SCHEMBL12228516 | 0.72 | NTRK1 (1.00) | NTRK1KDRPRKCQPRKCAFLT3 | |
| Lestaurtinib SCHEMBL17971365 | 0.72 | NTRK1 (1.00) | NTRK1KDRPRKCQPRKCAFLT3 | |
| Lestaurtinib SCHEMBL16139562 | 0.72 | NTRK1 (1.00) | NTRK1KDRPRKCQPRKCAFLT3 | |
| Lestaurtinib SCHEMBL13169434 | 0.72 | NTRK1 (1.00) | NTRK1KDRPRKCQPRKCAFLT3 | |
| Lestaurtinib SCHEMBL29625224 | 0.72 | NTRK1 (1.00) | NTRK1KDRPRKCQPRKCAFLT3 | |
| Lestaurtinib SCHEMBL17971367 | 0.72 | NTRK1 (1.00) | NTRK1KDRPRKCQPRKCAFLT3 | |
| Lestaurtinib SCHEMBL1649693 | 0.72 | NTRK1 (1.00) | NTRK1KDRPRKCQPRKCAFLT3 | |
| Lestaurtinib SCHEMBL12963759 | 0.72 | NTRK1 (1.00) | NTRK1KDRPRKCQPRKCAFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2752422-B1 | Stereoselective synthesis of phosphorus containing actives | GILEAD PHARMASSET LLC (US) | 2017-08-16 | — | — | EP | disclosed |
| US-8859756-B2 | Stereoselective synthesis of phosphorus containing actives | GILEAD PHARMASSET LLC (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2552931-B1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | GILEAD PHARMASSET LLC (US) | 2014-07-23 | — | — | EP | disclosed |
| EP-2752422-A1 | Stereoselective synthesis of phosphorus containing actives | Gilead Pharmasset LLC (US) | 2014-07-09 | — | — | EP | disclosed |
| US-20110245484-A1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | PHARMASSET, INC. (US) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245484-A1 | STEREOSELECTIVE SYNTHESIS OF PHOSPHORUS CONTAINING ACTIVES | PPA1, ENPP1, ITPA | NTRK1 4581/4885KDR 4309/4885PRKCQ 1015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.